The risks associated with RSV infection are especially pronounced among older adults, where it can lead to more severe complications and increased mortality rates. Recognising the importance of addressing this risk, the Australian Technical Advisory Group on Immunisation (ATAGI) recommends targeted vaccination strategies. Specifically, ATAGI recommends RSV vaccination for individuals over the age of 75 years, as well as Aboriginal and Torres Strait Islander people aged over 60 years. Additionally, individuals aged over 60 with medical conditions that heighten the risk of severe RSV disease are also recommended to receive vaccination.
Furthermore, ATAGI extends eligibility for RSV vaccination to all other individuals aged over 60 years, acknowledging the potential benefits of vaccination in reducing the burden of RSV-related illness across this age group.
In summary, RSV presents a significant health concern, particularly for vulnerable populations, including older adults. Getting vaccinated is the best way to mitigate the impact of RSV infections by targeting high-risk groups and extending eligibility to a broader segment of the older population.
